ANI Pharmaceuticals Completes $210m Novitium Acquisition
Acquisition Expected To Bolster R&D, Generics Scale And CDMO Business
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
You may also be interested in...
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.
ANI Pharmaceuticals and Eton Pharmaceuticals have announced the launch of their Carbaglu rival, with the companies having been granted a Competitive Generic Therapy designation by the FDA, along with 180 days of related exclusivity. ANI has also announced receiving FDA approval for its abbreviated new drug application for Mycobutin rival, Rifabutin capsules for 150mg dose.